Skip to main content
. 2020 Oct 2;56(3):605–613. doi: 10.1038/s41409-020-01069-w

Fig. 1. Outcome after alloHCT for patients with CLL who have been exposed to idelalisib.

Fig. 1

a, b Shows overall and progression-free survival with point-wise 95%-confidence intervals, respectively. c Shows the cumulative incidences of relapse and non-relapse mortality.